The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: A study in the biologics era

Rheumatology (United Kingdom)

Volumn 54, Issue 10, 2015, Pages 1780-1791

  Morgan, Catharine ^a   McBeth, John ^a,b   Cordingley, Lis ^a   Watson, Kath ^a   Hyrich, Kimme L ^a,c   Symmons, Deborah P M ^a,c   Bruce, Ian N ^a,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biologic therapy; Epidemiology; Illness perceptions; medication adherence; medication beliefs; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; ATTITUDE ASSESSMENT; ATTITUDE TO ILLNESS; BIOLOGICAL THERAPY; COHORT ANALYSIS; COMPLIANCE QUESTIONNAIRE FOR RHEUMATOLOGY; CONTROLLED STUDY; COPING BEHAVIOR; DAS28; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OBSERVATIONAL STUDY; ONSET AGE; PHYSICAL DISABILITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SHORT FORM 36; SOCIAL ISOLATION; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; CULTURAL ANTHROPOLOGY; LONGITUDINAL STUDY; PATIENT COMPLIANCE; PSYCHOLOGY; QUESTIONNAIRE; RETROSPECTIVE STUDY; SELF REPORT; SEVERITY OF ILLNESS INDEX; SOCIAL SUPPORT; TIME FACTOR; UNITED KINGDOM;

ADALIMUMAB; ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CULTURE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SELF REPORT; SEVERITY OF ILLNESS INDEX; SOCIAL SUPPORT; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; UNITED KINGDOM;

EID: 84943743987     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev105     Document Type: Article

References (50)

1. World Health Organisation. Adherence to Long-Term Therapies: Evidence for Action. 2003. http://whqlibdoc. who.int/publications/2003/9241545992.pdf (4 April 2015, date last accessed).
2. DiMatteo RM. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-9
3. de Klerk E, van der Heijde D, Landewe R et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44-54.
4. de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K. Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine. A prospective cohort study. Rheumatol Int 2009;30:1441-8
5. Treharne GJ, Lyons AC, Kitas GD. Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol Health Med 2004;9:337-49.
6. van den Bemt BJF, van den Hoogen FHJ, Benraad B et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009;36:2164-70
7. Borah BJ, Huang X, Zarotsky V, Globe D. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 2009;25:1365-77
8. Grijalva CG, Chung CP, Arbogast PG et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66-76
9. Hetland ML, Christensen IJ, Tarp U et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
10. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
11. Zink A, Listing J, Kary S et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 2005;64:1274-9
12. DiMatteo RM, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811
13. Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 2009;11:R26.
14. Viller F, Guillemin F, Briancon S et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999;26:2114-22
15. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res 2008;59:762-84
16. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
17. Brennan A, Bansback N, Nixon R et al. Modelling the cost effectiveness of TNF-a antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology 2007;46:1345-54
18. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
19. Dunbar-Jacob J, Holmes JL, Sereika S et al. Factors associated with attrition of African Americans during the recruitment phase of a clinical trial examining adherence among individuals with rheumatoid arthritis. Arthritis Rheum 2004;51:422-8
20. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883-9
21. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
22. Horne R, Weinman J. Self-regulation and selfmanagement in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17:17-32
23. Horne R, Chapman SCE, Parham R et al. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One 2013;8:e80633.
24. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res 1992;16:143-63
25. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24
26. Kennedy T, McCabe C, Struthers G et al. BSR guidelines on standards of care for persons with rheumatoid arthritis. Rheumatology 2005;44:553-6
27. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64(Suppl 4):iv42-3
28. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
29. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8
30. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J 1983;286:266.
31. Wener MH, Daum PR, McQuillan GM. The influence of age, sex and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000;27:2351-9
32. Department of Communities and Local Government. The English Index of Multiple Deprivation. 2010. http://www.gov.uk/government/statistics/englishindices- of-deprivation-2010 (4 April 2015, date last accessed).
33. Scottish Government. The Scottish Index of Multiple Deprivation. 2009. http://www.gov.scot/Topics/Statistics/SIMD/(4 April 2015, date last accessed).
34. Welsh Government. The Welsh Index of Multiple Deprivation. 2011. http://gov.wales/statistics-andresearch/welsh-index-multiple-deprivation/?lang=en (4 April 2015, date last accessed).
35. Fries JF, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
36. Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 Health Survey. Lincoln, RI, USA: QualityMetric, 2000.
37. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
38. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
39. Moss-Morris R, Weinman J, Petrie KJ et al. The revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002;17:1-16.
40. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70.
41. Newman SP, Revenson TA. Coping with rheumatoid arthritis. Baillieres Clin Rheumatol 1993;7:259-80.
42. de Klerk E, van der Heijde D, van der Tempel H, van der Linden S. Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol 1999;26:2635-41.
43. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnairerheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003;30:2469-75.
44. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
45. Rabe-Hesketh S, Skondal A. Multilevel and longitudinal modelling using STATA. 2nd edn. College Station, TX, USA: StataCorp, 2008:91-173.
46. Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology 2004;43:1034-8.
47. DiMatteo RM. Social support and patient adherence to medical treatment: a meta-analysis 1. Health Psychol 2004;23:207-18.
48. Owen SG, Friesen WT, Roberts MS, Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 1985;24:313-20.
49. Phillips LA, Leventhal H, Leventhal EA. Physicians' communication of the common-sense self-regulation model results in greater reported adherence than physicians' use of interpersonal skills. Br J Health Psychol 2011;17:244-57.
50. Porteous T, Francis J, Bond C, Hannaford P. Temporal stability of beliefs about medicines: implications for optimising adherence. Patient Educ Couns 2010;79:225-30.